August 8, 2017

JAK Inhibitor Upadacitinib Shows Promise in Hard To Treat Individuals with Rheumatoid Arthritis

By cancerconnect

Upadacitinib is a once daily oral medicine belongs to a new class of oral medicines called janus kinase or JAK inhibitors.  Janus kinases are enzymes that play a role in inflammation and RA.  JAK inhibitors block the activity of these enzymes leading to a reduction in inflammation and are showing significant benefit to individuals with RA

JAK Inhibitors-Next Advance in Treatment of Rheumatoid Arthritis

In a recently reported 12-week study evaluating two doses of upadacitinib 64 percent of patients given a 15-milligram dose and 66 percent of patients given a 30-mg dose experienced a 20 percent reduction in symptoms, measured using a commonly used rheumatoid arthritis scale.

In addition there are currently two new reports in the medical journal Arthritis & Rheumatology evaluating the effectiveness and safety of another selective JAK-1 inhibitor, ABT-494, in treating RA in individuals with an inadequate response to treatment with methotrexate (MTX) or a TNF inhibitor. 1,2,3

Taken together all these reports suggest JAK inhibitors are safe, effective and should become incorporated into the overall management of RA giving physicians a new tool for the management of this condition.

Upadacitinib is also being evaluating for several other autoimmune conditions, including psoriatic arthritis, Crohn's disease and ulcerative colitis.


  1. Genovese MC, Smolen JS, WEinblatt ME, et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808.
  2. Kremer JM, Emery P, Camp HS, et al. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801.
  3. Genovese M, Kremer J, Samani O, et al. Barcitinib in patients with refractory rheumatoid arthritis. New England Journal of Medicine. March 31, 2016. DOI: 10.1056/NEJMoa1507247

Tags: autoimmune conditions, crohn's disease, JAK inhibitors, janus kinase inhibitors, News Tips and Features, News Tips and Features Other, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Upadacitinib